Plasma levels of soluble amyloid precursor protein β in symptomatic Alzheimer’s disease

被引：0
作者：
Panagiotis Alexopoulos
Lena-Sophie Gleixner
Lukas Werle
Felix Buhl
Nathalie Thierjung
Evangelia Giourou
Simone M. Kagerbauer
Philippos Gourzis
Hubert Kübler
Timo Grimmer
Igor Yakushev
Jan Martin
Alexander Kurz
Robert Perneczky
机构：
[1] Technical University of Munich,Department of Psychiatry and Psychotherapy, Klinikum Rechts der Isar
[2] University Hospital of Rion,Department of Psychiatry
[3] University of Patras,Department of Anaesthesiology, Klinikum Rechts der Isar
[4] Max Planck Institute of Psychiatry,Department of Urology, Klinikum Rechts der Isar
[5] Technical University of Munich,Department of Nuclear Medicine, Klinikum Rechts der Isar
[6] Technical University of Munich,Department of Psychiatry and Psychotherapy
[7] Technical University of Munich,Neuroepidemiology and Ageing Research Unit, Faculty of Medicine, School of Public Health
[8] Ludwig-Maximilians-Universität München,undefined
[9] The Imperial College of Science,undefined
[10] Technology and Medicine,undefined
[11] West London Mental Health NHS Trust,undefined
[12] German Center for Neurodegenerative Diseases (DZNE) Munich,undefined
来源：
European Archives of Psychiatry and Clinical Neuroscience | 2018年 / 268卷
关键词：
Soluble amyloid precursor protein β (sAPPβ); Biomarker-underpinned diagnoses; FDG-PET; Upstream biomarkers; Mild cognitive impairment; Dementia due to Alzheimer’s disease;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The established biomarkers of Alzheimer’s disease (AD) require invasive endeavours or presuppose sophisticated technical equipment. Consequently, new biomarkers are needed. Here, we report that plasma levels of soluble amyloid precursor protein β (sAPPβ), a protein of the initial phase of the amyloid cascade, were significantly lower in patients with symptomatic AD (21 with mild cognitive impairment due to AD and 44 with AD dementia) with AD-typical cerebral hypometabolic pattern compared with 27 cognitively healthy elderly individuals without preclinical AD. These findings yield further evidence for the potential of sAPPβ in plasma as an AD biomarker candidate.
引用
收藏
页码：519 / 524
页数：5
相关论文
共 50 条
  • [41] Plasma neurofilament light chain levels in Alzheimer's disease
    Zhou, Wenjun
    Zhang, Jie
    Ye, Fanlong
    Xu, Guangzheng
    Su, Hang
    Su, Yindan
    Zhang, Xiangyang
    NEUROSCIENCE LETTERS, 2017, 650 : 60 - 64
  • [42] Soluble amyloid-beta isoforms predict downstream Alzheimer's disease pathology
    Povala, Guilherme
    Bellaver, Bruna
    De Bastiani, Marco Antonio
    Brum, Wagner S.
    Ferreira, Pamela C. L.
    Bieger, Andrei
    Pascoal, Tharick A.
    Benedet, Andrea L.
    Souza, Diogo O.
    Araujo, Ricardo M.
    Zatt, Bruno
    Rosa-Neto, Pedro
    Zimmer, Eduardo R.
    CELL AND BIOSCIENCE, 2021, 11 (01)
  • [43] Amyloid biomarkers in Alzheimer's disease
    Blennow, Kai
    Mattsson, Niklas
    Scholl, Michael
    Hansson, Oskar
    Zetterberg, Henrik
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2015, 36 (05) : 297 - 309
  • [44] Plasma amyloid-β and risk of Alzheimer's disease in the Framingham Heart Study
    Chouraki, Vincent
    Beiser, Alexa
    Younkin, Linda
    Preis, Sarah Rosner
    Weinstein, Galit
    Hansson, Oskar
    Skoog, Ingmar
    Lambert, Jean-Charles
    Au, Rhoda
    Launer, Lenore
    Wolf, Philip A.
    Younkin, Steven
    Seshadri, Sudha
    ALZHEIMERS & DEMENTIA, 2015, 11 (03) : 249 - 257
  • [45] Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker
    Jon B Toledo
    Leslie M Shaw
    John Q Trojanowski
    Alzheimer's Research & Therapy, 5
  • [46] Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease
    Roher, Alex E.
    Esh, Chera L.
    Kokjohn, Tyler A.
    Castano, Eduardo M.
    Van Vickle, Gregory D.
    Kalback, Walter M.
    Patton, R. Lyle
    Luehrs, Dean C.
    Daugs, Ian D.
    Kuo, Yu-Min
    Emmerling, Mark R.
    Soares, Holly
    Quinn, Joseph F.
    Kaye, Jeffrey
    Connor, Donald J.
    Silverberg, Nina B.
    Adler, Charles H.
    Seward, James D.
    Beach, Thomas G.
    Sabbagh, Marwan N.
    ALZHEIMERS & DEMENTIA, 2009, 5 (01) : 18 - 29
  • [47] Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease
    Rembach, Alan
    Faux, Noel G.
    Watt, Andrew D.
    Pertile, Kelly K.
    Rumble, Rebecca L.
    Trounson, Brett O.
    Fowler, Christopher J.
    Roberts, Blaine R.
    Perez, Keyla A.
    Li, Qiao-Xin
    Laws, Simon M.
    Taddei, Kevin
    Rainey-Smith, Stephanie
    Robertson, Joanne S.
    Vandijck, Manu
    Vanderstichele, Hugo
    Barnham, Kevin J.
    Ellis, Kathryn A.
    Szoeke, Cassandra
    Macaulay, Lance
    Rowe, Christopher C.
    Villemagne, Victor L.
    Ames, David
    Martins, Ralph N.
    Bush, Ashley I.
    Masters, Cohn L.
    ALZHEIMERS & DEMENTIA, 2014, 10 (01) : 53 - 61
  • [48] Amyloid imaging in Alzheimer's disease
    Nordberg, Agneta
    CURRENT OPINION IN NEUROLOGY, 2007, 20 (04) : 398 - 402
  • [49] Plasma Amyloid-β as a Biomarker in Alzheimer's Disease: The AIBL Study of Aging
    Lui, James K.
    Laws, Simon M.
    Li, Qiao-Xin
    Villemagne, Victor L.
    Ames, David
    Brown, Belinda
    Bush, Ashley I.
    De Ruyck, Karl
    Dromey, Jasmin
    Ellis, Kathryn A.
    Faux, Noel G.
    Foster, Jonathan
    Fowler, Christopher
    Gupta, Veer
    Hudson, Peter
    Laughton, Katrina
    Masters, Colin L.
    Pertile, Kelly
    Rembach, Alan
    Rimajova, Mira
    Rodrigues, Mark
    Rowe, Christopher C.
    Rumble, Rebecca
    Szoeke, Cassandra
    Taddei, Kevin
    Taddei, Tania
    Trounson, Brett
    Ward, Vanessa
    Martins, Ralph N.
    JOURNAL OF ALZHEIMERS DISEASE, 2010, 20 (04) : 1233 - 1242
  • [50] Amyloid β-peptide and Alzheimer's disease
    Allsop, David
    Mayes, Jennifer
    AMYLOIDS IN HEALTH AND DISEASE, 2014, 56 : 99 - 110
12345